Circassia Pharmaceuticals’ (CIR) “Buy” Rating Reaffirmed at Numis Securities
Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reaffirmed by investment analysts at Numis Securities in a note issued to investors on Monday, December 4th, MarketBeat Ratings reports. They currently have a GBX 180 ($2.41) target price on the biopharmaceutical company’s stock. Numis Securities’ target price would indicate a potential upside of 80.00% from the company’s previous close.
Other equities research analysts have also issued reports about the company. Peel Hunt reissued a “hold” rating and issued a GBX 130 ($1.74) price target on shares of Circassia Pharmaceuticals in a research report on Wednesday, September 27th. JPMorgan Chase & Co. decreased their target price on Circassia Pharmaceuticals from GBX 120 ($1.60) to GBX 110 ($1.47) and set a “neutral” rating for the company in a research report on Thursday, September 28th.
Circassia Pharmaceuticals (CIR) remained flat at $GBX 100 ($1.34) during midday trading on Monday. The firm has a market capitalization of $333.47 and a P/E ratio of -454.55. Circassia Pharmaceuticals has a 12 month low of GBX 76.75 ($1.03) and a 12 month high of GBX 115.61 ($1.55).
WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/25/circassia-pharmaceuticals-cir-buy-rating-reaffirmed-at-numis-securities.html.
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.